Int J Drug Policy

ISSN 0955-3959; 1873-4758;

4 papers in the library · 29 citations · publishing 2012-2025

Papers

Sort Most recent Most cited

Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.

Int J Drug Policy December 13, 2025 Michelle Olofsson, Walter Osika, Simon B. Goldberg et al. 2 citations

BACKGROUND: Naturalistic psychedelic use can result in a range of difficulties that impair social, occupational, and other important areas of functioning. Yet, the prevalence, phenomenology, and etiology of these outcomes remain poorly understood. Recent qualitative research has shown that individuals with long-term difficulties after psychedelic use sometimes attribute their challenges to...

DOI: 10.1016/j.drugpo.2025.105105 Full text

Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?

Int J Drug Policy July 26, 2024 Sharon R. Sznitman, Barbara Broers, Reto Auer et al. 1 citation

Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?

DOI: 10.1016/j.drugpo.2024.104521 Psychedelic therapy Psychedelic-assisted therapy Psychedelic medicine Psychedelic treatment +16

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

Int J Drug Policy November 7, 2021

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

DOI: 10.1016/j.drugpo.2021.103518 Full text

Statement on ayahuasca.

Int J Drug Policy March 27, 2012 Brian T Anderson, Beatriz C. Labate, Matthew Meyer et al. 26 citations

Statement on ayahuasca.

DOI: 10.1016/j.drugpo.2012.02.007 Mental health Well-being Psychological health Emotional health +20